硬皮病胃肠道受累的管理
Management of gastrointestinal involvement in scleroderma.
作者信息
Nagaraja Vivek, McMahan Zsuzsanna H, Getzug Terri, Khanna Dinesh
机构信息
Division of Rheumatology, University of Toledo, Toledo, Ohio.
Division of Rheumatology, John Hopkins University, Baltimore, Maryland.
出版信息
Curr Treatm Opt Rheumatol. 2015 Mar 1;1(1):82-105. doi: 10.1007/s40674-014-0005-0.
Abstract
Gastrointestinal tract (GIT) commonly affects patients with systemic sclerosis (SSc). The GI involvement is quite heterogeneous varying from asymptomatic disease to significant dysmotility causing complications like malabsorption, weight loss and severe malnutrition. This review focuses on the management of GI involvement in SSc and has been categorized based on the segment of GIT involved. A brief discussion on the role of patient reported outcome measures in SSc-GI involvement has also been incorporated.
摘要
胃肠道（GIT）常累及系统性硬化症（SSc）患者。胃肠道受累情况差异很大，从无症状疾病到导致吸收不良、体重减轻和严重营养不良等并发症的显著动力障碍。本综述重点关注系统性硬化症胃肠道受累的管理，并根据受累的胃肠道节段进行了分类。还简要讨论了患者报告结局指标在系统性硬化症胃肠道受累中的作用。
相似文献
1
Management of gastrointestinal involvement in scleroderma.
Curr Treatm Opt Rheumatol. 2015 Mar 1;1(1):82-105. doi: 10.1007/s40674-014-0005-0.
2
[Gastrointestinal features in systemic sclerosis].
Rev Med Suisse. 2014 Apr 16;10(426):860-3.
3
Severe gastrointestinal involvement in systemic sclerosis: report of five cases and review of the literature.
Semin Arthritis Rheum. 2005 Feb;34(4):689-702. doi: 10.1016/j.semarthrit.2004.08.009.
4
Responsiveness of the University of California Los Angeles Scleroderma Clinical Trial Consortium gastrointestinal tract 2.0 (UCLA-SCTC-GIT 2.0)to change in scleroderma patients.
J Scleroderma Relat Disord. 2021 Oct;6(3):236-241. doi: 10.1177/2397198321992197. Epub 2021 Feb 22.
5
A Phenome-Wide Association Study of Drugs and Comorbidities Associated With Gastrointestinal Dysfunction in Systemic Sclerosis.
J Rheumatol. 2023 Jul;50(7):907-915. doi: 10.3899/jrheum.220990. Epub 2023 Feb 15.
6
The Unusual Suspect: An Acute Gastric Dilation With Volvulus in a Scleroderma Patient.
Cureus. 2022 Mar 24;14(3):e23436. doi: 10.7759/cureus.23436. eCollection 2022 Mar.
7
Nutrition in systemic sclerosis.
Reumatol Clin. 2012 May-Jun;8(3):135-40. doi: 10.1016/j.reuma.2011.09.006. Epub 2011 Dec 24.
8
Validation of Serbian version of UCLA Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument in 104 patients with systemic sclerosis.
Rheumatol Int. 2017 May;37(5):735-741. doi: 10.1007/s00296-017-3680-y. Epub 2017 Mar 7.
9
UCLA Scleroderma Clinical Trials Consortium Gastrointestinal Tract (GIT) 2.0 Reflux Scale Correlates With Impaired Esophageal Scintigraphy Findings in Systemic Sclerosis.
J Rheumatol. 2021 Sep;48(9):1422-1426. doi: 10.3899/jrheum.201283. Epub 2021 Jan 15.
10
Gastrointestinal manifestations of scleroderma: recent progress in evaluation, pathogenesis, and management.
Curr Rheumatol Rep. 2012 Feb;14(1):22-9. doi: 10.1007/s11926-011-0217-3.
引用本文的文献
1
Drug treatment strategies for erosive esophagitis in adults: a narrative review.
Transl Gastroenterol Hepatol. 2025 Jul 23;10:54. doi: 10.21037/tgh-24-168. eCollection 2025.
2
Rheumatologists' Adherence to EULAR Recommendations for Systemic Sclerosis Treatment: Experience of a Single Center in Serbia.
J Clin Med. 2025 Jul 15;14(14):4994. doi: 10.3390/jcm14144994.
3
Bidirectional endoscopic and pharmacological approach for the treatment of severe right-sided colonic stool impaction.
BMJ Case Rep. 2025 Apr 29;18(4):e263383. doi: 10.1136/bcr-2024-263383.
4
Evidence for targeting autonomic dysfunction in systemic sclerosis: A scoping review.
J Scleroderma Relat Disord. 2025 Jan 8:23971983241308050. doi: 10.1177/23971983241308050.
5
The frequency and clinical associations of opioid use in systemic sclerosis.
Rheumatol Adv Pract. 2024 Nov 15;8(4):rkae144. doi: 10.1093/rap/rkae144. eCollection 2024.
6
Views of nutrition needs in patients with systemic sclerosis.
J Scleroderma Relat Disord. 2024 Oct;9(3):216-222. doi: 10.1177/23971983241264868. Epub 2024 Aug 8.
7
Demographics and clinical features associated with abnormal small bowel motility in systemic sclerosis.
Rheumatology (Oxford). 2025 May 1;64(5):2775-2782. doi: 10.1093/rheumatology/keae542.
8
Effects of probiotics supplementation in gastrointestinal complications and quality of life of patients with systemic sclerosis: A systematic review.
Heliyon. 2024 Aug 13;10(16):e36230. doi: 10.1016/j.heliyon.2024.e36230. eCollection 2024 Aug 30.
9
Gastric dysrhythmias in patients with early systemic sclerosis: a cross-sectional study.
Rheumatol Adv Pract. 2024 Mar 12;8(2):rkae041. doi: 10.1093/rap/rkae041. eCollection 2024.
10
Approach to esophageal absent contractility: can we do better?
Ann Gastroenterol. 2024 Mar-Apr;37(2):117-124. doi: 10.20524/aog.2024.0860. Epub 2024 Feb 13.
本文引用的文献
1
Effects of baclofen on the functional anatomy of the oesophago-gastric junction and proximal stomach in healthy volunteers and patients with GERD assessed by magnetic resonance imaging and high-resolution manometry: a randomised controlled double-blind study.
Aliment Pharmacol Ther. 2014 Nov;40(10):1230-40. doi: 10.1111/apt.12956. Epub 2014 Sep 17.
2
Development of the NIH Patient-Reported Outcomes Measurement Information System (PROMIS) gastrointestinal symptom scales.
Am J Gastroenterol. 2014 Nov;109(11):1804-14. doi: 10.1038/ajg.2014.237. Epub 2014 Sep 9.
3
Mortality, recurrence, and hospital course of patients with systemic sclerosis-related acute intestinal pseudo-obstruction.
J Rheumatol. 2014 Oct;41(10):2049-54. doi: 10.3899/jrheum.131547. Epub 2014 Aug 15.
4
Diets that differ in their FODMAP content alter the colonic luminal microenvironment.
Gut. 2015 Jan;64(1):93-100. doi: 10.1136/gutjnl-2014-307264. Epub 2014 Jul 12.
5
Breath tests in the diagnosis of small intestinal bacterial overgrowth in patients with irritable bowel syndrome in comparison with quantitative upper gut aspirate culture.
Eur J Gastroenterol Hepatol. 2014 Jul;26(7):753-60. doi: 10.1097/MEG.0000000000000122.
6
Clinical effects of ghrelin on gastrointestinal involvement in patients with systemic sclerosis.
Endocr J. 2014;61(7):735-42. doi: 10.1507/endocrj.ej14-0088. Epub 2014 May 17.
7
Construct validity of the Patient-Reported Outcomes Measurement Information System gastrointestinal symptom scales in systemic sclerosis.
Arthritis Care Res (Hoboken). 2014 Nov;66(11):1725-30. doi: 10.1002/acr.22337.
8
Acupuncture-based modalities: novel alternative approaches in the treatment of gastrointestinal dysmotility in patients with systemic sclerosis.
Explore (NY). 2014 Jan-Feb;10(1):44-52. doi: 10.1016/j.explore.2013.10.001. Epub 2013 Oct 17.
9
Small intestinal bacterial overgrowth: what it is and what it is not.
Curr Opin Gastroenterol. 2014 Mar;30(2):141-6. doi: 10.1097/MOG.0000000000000040.
10
Proton pump inhibitor therapy and potential long-term harm.
Curr Opin Endocrinol Diabetes Obes. 2014 Feb;21(1):3-8. doi: 10.1097/MED.0000000000000031.
Zotero 插件